Osimertinib is the first mutant-selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for patients with EGFR oncogene-addicted advanced non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.